REED JOHN C
SEC CIK 1181561 · EDGAR
BoughtSold
Most active insiders at MDGL, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | FRIEDMAN PAUL A | Dir | — | $26.66M |
| 2 | Taub Rebecca | Dir | — | $21.68M |
| 3 | Sibold William John | Pres, CEO, Dir | — | $10.48M |
| 4 | BATE KENNETH | Dir | — | $8.03M |
| 5 | Levy Richard S | Dir | — | $7.36M |
| 6 | Dier Mardi | EVP, CFO | — | $3.77M |
| 7 | Huntsman Carole | Chief Commercial Off | — | $1.71M |
| 8 | Soergel David | Chief Medical Off | — | $952.0K |
| 9 | Kelley Shannon T | GC | — | $841.6K |
| 10 | Thakkar Rita | CAO | — | — |
| 15 | REED JOHN C | Dir | — | — |
Transactions 17
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-18 17:10 | 2026-08-15 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | REED JOHN C | Dir | A - Grant | $0.00 | +647 | 647 | New | $0 |
| D | 2026-05-04 16:58 | 2026-05-01 | JNJ | Johnson & Johnson | REED JOHN C | EVP, Innovative Medicine, R, D | M - OptEx | $0.00 | +25.3K | 35.9K | +237% | $0 |
| D | 2026-05-04 16:58 | 2026-05-01 | JNJ | Johnson & Johnson | REED JOHN C | EVP, Innovative Medicine, R, D | F - Tax | $229.85 | -11.0K | 24.9K | -31% | -$2.53M |
| DM | 2026-02-18 21:12 | 2026-02-15+ | JNJ | Johnson & Johnson | REED JOHN C | EVP, Innovative Medicine, R, D | M - OptEx | $147.75 | +54.8K | 42.9K | New | +$8.10M |
| DM | 2026-02-18 21:12 | 2026-02-15 | JNJ | Johnson & Johnson | REED JOHN C | EVP, Innovative Medicine, R, D | F - Tax | $243.45 | -913 | 12.9K | -7% | -$222.3K |
| DM | 2026-02-18 21:12 | 2026-02-17 | JNJ | Johnson & Johnson | REED JOHN C | EVP, Innovative Medicine, R, D | S - Sale+OE | $243.00 | -53.9K | 10.7K | -83% | -$13.11M |
| D | 2025-10-20 19:13 | 2025-10-17 | JNJ | Johnson & Johnson | REED JOHN C | EVP, Innovative Medicine, R, D | M - OptEx | $157.92 | +21.7K | 32.4K | +204% | +$3.43M |
| D | 2025-10-20 19:13 | 2025-10-17 | JNJ | Johnson & Johnson | REED JOHN C | EVP, Innovative Medicine, R, D | S - Sale+OE | $192.71 | -21.7K | 10.7K | -67% | -$4.19M |
| 2025-07-18 16:12 | 2025-07-17 | JNJ | Johnson & Johnson | REED JOHN C | EVP, Innovative Medicine, R, D | S - Sale | $163.55 | -19.1K | 10.7K | -64% | -$3.13M | |
| D | 2025-05-05 17:10 | 2025-05-01 | JNJ | Johnson & Johnson | REED JOHN C | EVP, Innovative Medicine, R, D | M - OptEx | $0.00 | +25.3K | 40.8K | +162% | $0 |
| D | 2025-05-05 17:10 | 2025-05-01 | JNJ | Johnson & Johnson | REED JOHN C | EVP, Innovative Medicine, R, D | F - Tax | $156.31 | -11.0K | 29.8K | -27% | -$1.72M |
| D | 2025-02-18 21:11 | 2025-02-15 | JNJ | Johnson & Johnson | REED JOHN C | EVP, Innovative Medicine, R, D | M - OptEx | $0.00 | +1,350 | 15.9K | +9% | $0 |
| D | 2025-02-18 21:11 | 2025-02-18 | JNJ | Johnson & Johnson | REED JOHN C | EVP, Innovative Medicine, R, D | F - Tax | $156.15 | -385 | 15.5K | -2% | -$60.1K |
| DA | 2024-10-31 17:57 | 2024-05-01 | JNJ | Johnson & Johnson | REED JOHN C | EVP, Innovative Medicine, R, D | M - OptEx | $0.00 | +25.3K | 25.6K | +8,253% | $0 |
| DA | 2024-10-31 17:57 | 2024-05-01 | JNJ | Johnson & Johnson | REED JOHN C | EVP, Innovative Medicine, R, D | F - Tax | $144.59 | -11.0K | 14.6K | -43% | -$1.59M |
| D | 2024-05-03 16:31 | 2024-05-01 | JNJ | Johnson & Johnson | REED JOHN C | EVP, Innovative Medicine, R, D | M - OptEx | $0.00 | +22.3K | 22.6K | +7,273% | $0 |
| D | 2024-05-03 16:31 | 2024-05-01 | JNJ | Johnson & Johnson | REED JOHN C | EVP, Innovative Medicine, R, D | F - Tax | $144.59 | -11.0K | 11.6K | -49% | -$1.59M |
Purchase Sale Sale after option exercise All abbreviations